

BIOSTOCK PUBLISHES ARTICLE AFTER PROLIGHT SIGNED SUPPLY AGREEMENT WITH BRAINBOX VALUED AT USD 3.9 MILLION

BioStock publishes article after Prolight Diagnostics signed supply agreement with BRAINBox valued at USD 3.9 million during the first year, with comments from Prolight.

Read the full article here: <https://biostock.se/en/2026/09/prolight-comments-on-usd-3-9m-brainbox-deal/>

For further information, please contact:

Ulf Bladin, CEO

E-mail: info@prolightdx.com

Phone: +46 73 582 39 87

Company website: www.prolightdx.com

About Us

Prolight Diagnostics develops Psyros[®], a groundbreaking Point-of-Care platform for highly sensitive biomarker diagnostics. By delivering reliable test results in ten minutes or less, Psyros has the potential to revolutionize clinical workflows, improve patient outcomes, and reduce healthcare costs. The platform is initially being developed for areas with significant unmet medical needs such as cardiovascular and neurological conditions and possesses broad potential for a wide range of clinical applications.

The company's share is traded on the NGM Growth Market marketplace, under the ticker PRLD.

Attachments

BioStock publishes article after Prolight signed supply agreement with BRAINBox valued at USD 3.9 million